ReviewFrontiers in oncology2026
The mechanism of action, clinical significance, and research progress of tumor antigen-specific T cells in the treatment of HCC.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a malignancy characterised by high incidence and mortality rates, with China accounting for over 50% of new cases and deaths globally. The prevention and treatment of HCC remain formidable challenges, primarily due to pronounced tumour heterogeneity and a complex immune microenvironment. Recent advances in immunotherapy have highlighted the critical role of tumour antigen-specific T cells (TASCs) in the management of HCC. This review systematically examines the mechanisms underlying TASCs function, recent advances in HCC research, and the clinical significance of TASCs detection. It further analyses current challenges in HCC immunotherapy and offers a theoretical foundation and prospective directions for the development of combination and personalised therapies targeting TASCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.